* Stribild, a new combination anti-HIV drug, has been approved by the Food and Drug Administration. The product contains two new drugs, elvitegravir and cobicistat, and two previously approved drugs, emtricitabine and tenofovir.
* Given once daily to treatment-naïve patients with HIV-1, Stribild is considered a complete treatment for HIV. This decreases the pill burden and should aid in promoting treatment adherence.
* Stribild's label carries boxed warnings similar to the labels of some other HIV drugs.